Physician profile
Robert Decolli
NPI 1790778991
$4,332.41
in general payments reported to CMS, 2019-2025
28 companies · $50.42 in 2025
The $50.42 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,383 · 2020: $1,560 · 2023: $187 · 2024: $151 · 2025: $50.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $388.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $837.57 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $585.80 | 2019-2020 | |
| Glaxosmithkline, LLC. | $409.31 | 2019-2023 | Bexsero, Pediarix, Arexvy |
| Pfizer INC. | $335.99 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $281.93 | 2019-2020 | |
| Boston Scientific Corporation | $254.77 | 2019-2020 | |
| Amgen INC. | $216.61 | 2019-2020 | |
| Lilly USA, LLC | $212.24 | 2019-2025 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.11 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $143.03 | 2019-2024 | Capvaxive |
| Amarin Pharma, INC. | $132.23 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $120.02 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $99.81 | 2024 | Amvuttra |
| Astellas Pharma US INC | $98.86 | 2019-2020 | |
| Allergan, INC. | $87.20 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $70.01 | 2019 | |
| Avanir Pharmaceuticals, INC. | $61.41 | 2019-2020 | |
| Abbvie INC. | $49.69 | 2024-2025 | |
| Mylan Specialty L.P. | $36.88 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.08 | 2020 | |
| Gilead Sciences, INC. | $24.29 | 2023 | Biktarvy |
| Exact Sciences Corporation | $15.97 | 2025 | The Cologuard Plus Collection Kit |
| Ibsa Pharma INC. | $15.58 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.21 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $12.26 | 2020 | |
| Sanofi Pasteur INC. | $12.26 | 2019 | |
| Philips North America LLC | $12.14 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Decolli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.